BioStem Q3 Loss Widens to $11.4M; Cash Falls to $1.0M as Guidance Is Raised
BSEM sits 31% above its 52-week low of $1 on elevated volume (2.1× avg).
Summary
BioStem posted a $11.4M Q3 net loss on $7.6M of revenue with cash down to $1.0M, but raised full-year revenue guidance to $28M-$29M and outlined $10M-$12M of annualized cost cuts.
Key Events · Earnings and Guidance · BSEM
-
Q3 Revenue Falls, Loss Widens
Net revenue was $7.6M versus $10.5M a year earlier, and the GAAP net loss was $11.4M, or $0.64 per share, compared with net income of $0.8M in Q3 2025.
-
Cash Drops to $1.0M
Cash and equivalents fell to $1.0M at September 30, 2026 from $7.0M at June 30, 2026, with $8.8M used in operations during the quarter.
-
Full-Year Guidance Raised
Full-year 2026 revenue guidance was raised to $28M-$29M from the prior $26M-$29M range.
-
Cost Cuts of $10M-$12M Planned
A cost reduction plan is being finalized, expected to cut annualized cash operating expenses by roughly $10M-$12M versus the current run rate, with full benefit beginning in Q1 2027.
Analysis · BSEM · Life Sciences
The headline is deteriorating fundamentals: Q3 net revenue fell to $7.6M from $10.5M a year ago, and the GAAP net loss widened to $11.4M, or $0.64 per share. Cash dropped to $1.0M from $7.0M in the prior quarter, and the $10.0M Clearance Payment owed to BioTissue remains unpaid and is being renegotiated. Against that, management raised full-year revenue guidance to $28M-$29M and is finalizing a plan to cut $10M-$12M of annualized cash operating expenses, with full benefit starting in Q1 2027. The company is leaning on the $40M Roth equity facility, but sales under it cannot begin until early April 2027 unless the restriction is waived, so near-term liquidity depends on the BioTissue restructuring and the cost cuts.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $1.00 to $8.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.